Thursday 27 October 2016

Immune checkpoint-related neurotoxicity may be more common during combination treatment

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors such as nivolumab and pembrolizumab, but it may be more common in patients treated with nivolumab plus a CTLA-4-blocking antibody such as ipilimumab, a study published in the journal Annals of Oncology has shown.

Read more here.

Study mentioned:

Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2016 Oct 25. doi: 10.1093/annonc/mdw558.

No comments:

Post a Comment